Abstract
Background Reliable biomarkers ofv androgen activity in humans are lacking. The aim of this study was, therefore, to identify new protein markers of biological androgen activity and test their predictive value in relation to low vs. normal testosterone values and some androgen deficiency linked pathologies.
Methods Blood samples from 30 healthy GnRH-antagonist treated males were collected at three time points: a) before GnRH antagonist administration; b) 3 weeks later, just before testosterone undecanoate injection, and c) after additional 2 weeks. Subsequently they were analysed by mass spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins most significantly associated with testosterone fluctuations were further tested in a cohort of 75 hypo- and eugonadal males suffering from infertility. Associations between levels of those markers and cardio-metabolic parameters, bone mineral density as well as androgen receptor CAG repeat lengths, were explored.
Results Using ROC analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6) and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/L) vs. normal (> 12 nmol/L) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD levels also showed association with AR CAG-repeat lengths.
Conclusions We identified potential new protein biomarkers of testosterone action. Further investigations to eluciadate their clinical potential are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
http://clinicaltrials.gov, Registration number: NCT03541395, date of registration May 17th, 2018
Funding Statement
The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by the Interreg V EU program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All subjects were enrolled with informed written consent. The two studies from which they were recruited were approved by the Swedish Ethical Review Authority (Approval number: DNR 2014/311, date of approval 8 May 2014; DNR 2011/1, date of approval 11 January 2011).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
↵*† The authors share the first and last positions.
Funding: The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by the Interreg V EU program.
Data Availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD024448. Supplementary tables (datasets) and source data can be found on: https://doi.org/10.6084/m9.figshare.14875431. Supplementary Figure S1: https://doi.org/10.6084/m9.figshare.14876562. R code: https://github.com/indirapla/TP1_proteins_marker_of_androgen_activity.
